Enliven Therapeutics (ELVN) Other Non Operating Income (2019 - 2025)
Enliven Therapeutics' (ELVN) quarterly Other Non Operating Income came in at -$2000.0 in Q2 2025, down 100.0% year-on-year from -$inf billion in Q2 2024, and up 95.74% quarter-over-quarter from -$47000.0 in Q1 2025.
Enliven Therapeutics (ELVN) Other Non Operating Income (2019 - 2025) Analysis & Trends
Enliven Therapeutics has disclosed Other Non Operating Income across 7 years of filings, most recently posting -$2000.0 for Q2 2025.
- Other Non Operating Income for Q2 2025 came in at -$2000.0, down 100.0% year-over-year; the trailing twelve-month figure through Mar 2026 was -$2000.0 (up 95.83% YoY), and the FY2025 annual result was -$49000.0, down 2350.0% from the prior year.
- Other Non Operating Income came in at -$2000.0 for Q2 2025 at Enliven Therapeutics, up from -$47000.0 in the prior quarter.
- In the past five years, Other Non Operating Income ranged from a high of -$1000.0 in Q1 2024 to a low of -$60000.0 in Q1 2021.
- The 5-year median for Other Non Operating Income is -$28000.0 (2021), against an average of -$28500.0.
- Across the five-year window, Other Non Operating Income surged 67.27% in 2021 and sank 4600.0% in 2025, its largest moves.
- Enliven Therapeutics' Other Non Operating Income stood at -$57000.0 in 2021, then surged by 33.33% to -$38000.0 in 2022, then surged by 76.32% to -$9000.0 in 2023, then jumped by 88.89% to -$1000.0 in 2024, then sank by 100.0% to -$2000.0 in 2025.
- The last three Other Non Operating Income figures came in at -$2000.0 (Q2 2025), -$47000.0 (Q1 2025), and -$1000.0 (Q2 2024), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 762,369.55 Bn | 762,369.51 Bn | - |
| 2 | Belite Bio | 55,096.00 Bn | 55,096.00 Bn | - |
| 3 | Quantum Biopharma | 17,755.80 Bn | 17,755.79 Bn | - |
| 4 | Legend Biotech | 3,486.00 Bn | 3,485.71 Bn | 242.10 Mn |
| 5 | Akari Therapeutics | 1,737.42 Bn | 1,737.41 Bn | - |
| 6 | Evaxion A | 1,551.28 Bn | 1,551.26 Bn | - |
| 7 | Psyence Biomedical | 227.32 Bn | 227.31 Bn | - |
| 8 | Vertex Pharmaceuticals | 110.84 Bn | 103.59 Bn | 2.59 Bn |
| 9 | Abivax | 91.71 Bn | 91.71 Bn | - |
| 10 | Enliven Therapeutics | 2.32 Bn | 2.32 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2025 | -2,000.00 |
| Mar 31, 2025 | -47,000.00 |
| Jun 30, 2024 | -1,000.00 |
| Mar 31, 2024 | -1,000.00 |
| Dec 31, 2023 | -9,000.00 |
| Sep 30, 2023 | -13,000.00 |
| Jun 30, 2022 | -38,000.00 |
| Mar 31, 2022 | -56,000.00 |
| Dec 31, 2021 | -57,000.00 |
| Sep 30, 2021 | -18,000.00 |
| Jun 30, 2021 | -40,000.00 |
| Mar 31, 2021 | -60,000.00 |
| Dec 31, 2020 | -83,000.00 |
| Sep 30, 2020 | -55,000.00 |
| Jun 30, 2020 | -12,000.00 |
| Mar 31, 2020 | 5,000.00 |
| Dec 31, 2019 | 69,000.00 |
| Sep 30, 2019 | 6,000.00 |